Immune cells of the brain and spinal cord, called microglia, contribute to the cognitive deficits seen in some systemic lupus erythematosus (SLE) patients by trimming neurons in the central nervous system, researchers at The Feinstein Institute for Medical Research suggest.
Lupus affects nine times more women than men. Experts know that lupus erythematosus, SLE, or lupus affects many more women than men, but none of them can explain why. Now that University of Houston biomedical engineer Chandra Mohan has the funding, he has set out to determine why.
Prof. Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, has $2 million to solve the mystery.
The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
According to the data, a statistically significant proportion of patients treated with 4mg of Olumiant (baricitinib) achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, thus meeting the primary endpoint of the trial.
The Lupus Research Alliance is pleased and very encouraged to share a promising scientific breakthrough reported in the New York Times with real potential to revolutionize lupus treatment. Just reported in the prestigious journal Nature, scientists in Dr. Alexander Marson's lab at the University of California, San Francisco have developed an innovative way to engineer genes of the body's immune system to treat immunologic diseases like lupus, rheumatoid arthritis, cancer and HIV.
Two studies by researchers at UT Southwestern Medical Center could lead to new treatments for lupus and other autoimmune diseases and strengthen therapies for viral, bacterial, and parasitic infections.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN)...
Steroids, older age worsen Lupus damage. Despite significant improvements in treatment during recent decades, patients with systemic lupus erythematosus remain at risk for disease damage...
Patients with SLE had more sleep problems than the general US population, and psychosocial factors, particularly depression and anxiety, were associated with the abnormalities, according to recent study results from the University of Chicago Rheumatology clinic.
Scientists at Yale University have designed and tested a drug delivery system that shows early promise for improved treatment of lupus and other chronic, uncured autoimmune diseases, such as multiple sclerosis and Type 1 diabetes...